Background
Methods
Patient selection
Operative procedure
Data collection
Propensity score analysis
Statistical analyses
Results
Patient characteristics
Variable | Before PSM (n = 204) | aAfter PSM (n = 78) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
D1/D1+ (n = 54) | D2 (n = 150) | D1/D1+ (n = 39) | D2 (n = 39) | ||||||||
54 | 150 | 39 | 39 | ||||||||
n
| % |
n
| % |
p
b
|
n
| % |
n
| % |
p
b
| ||
Aged | Mean (sd) | c67.1 | c(11.7) | c65.5 | c(12.75) | 0.420 | c67.4 | c(11.5) | 64.9 | c(13.5) | 0.387 |
Gender | 0.604 | 1.000 | |||||||||
Male | 35 | (65%) | 103 | (69%) | 27 | (69%) | 27 | (69%) | |||
Female | 19 | (35%) | 47 | (31%) | 12 | (31%) | 12 | (31%) | |||
BMIe | Mean (sd) | c26.7 | c(5.46) | c24.8 | c(5.58) | 0.049* | c26.0 | c(5.29) | c24.4 | c(6.35) | 0.219 |
Hemoglobin level | 0.932 | 0.530 | |||||||||
≤ 100 g/L | 7 | (13%) | 20 | (13%) | 5 | (13%) | 7 | (18%) | |||
> 100 g/L | 47 | (87%) | 129 | (86%) | 34 | (87%) | 32 | (82%) | |||
Tumor location | 0.168 | 0.193 | |||||||||
Proximal | 5 | (9%) | 30 | (20%) | 4 | (10%) | 6 | (15%) | |||
Middle | 15 | (28%) | 31 | (21%) | 11 | (28%) | 17 | (44%) | |||
Distal | 28 | (52%) | 79 | (53%) | 24 | (62%) | 16 | (41%) | |||
TMN stage | 0.119 | 0.280 | |||||||||
In situ | 0 | (0%) | 4 | (3%) | 0 | (0%) | 4 | (10%) | |||
I | 19 | (35%) | 44 | (29%) | 14 | (36%) | 16 | (41%) | |||
II | 19 | (35%) | 49 | (33%) | 14 | (36%) | 11 | (28%) | |||
III | 12 | (22%) | 48 | (32%) | 9 | (23%) | 7 | (18%) | |||
IV | 4 | (7%) | 3 | (2%) | 2 | (5%) | 1 | (3%) | |||
Unknown | 0 | (0%) | 2 | (1%) | 0 | (0%) | 0 | (0%) | |||
T level | 0.123 | 0.411 | |||||||||
T0 | 0 | (0%) | 4 | (3%) | 0 | (0%) | 2 | (5%) | |||
T1 | 15 | (28%) | 39 | (26%) | 11 | (28%) | 12 | (31%) | |||
T2 | 8 | (15%) | 18 | (12%) | 7 | (18%) | 7 | (18%) | |||
T3 | 22 | (41%) | 39 | (26%) | 15 | (38%) | 10 | (26%) | |||
T4 | 9 | (17%) | 48 | (32%) | 6 | (15%) | 6 | (15%) | |||
Unknown | 0 | (0%) | 2 | (1%) | 0 | (0%) | 2 | (5%) | |||
N category | 0.831 | 0.523 | |||||||||
N0 | 26 | (48%) | 65 | (43%) | 18 | (46%) | 20 | (51%) | |||
N1 | 12 | (22%) | 35 | (23%) | 9 | (23%) | 12 | (31%) | |||
N2 | 7 | (13%) | 27 | (18%) | 5 | (13%) | 4 | (10%) | |||
N3 | 9 | (17%) | 23 | (15%) | 7 | (18%) | 3 | (8%) | |||
Differentiation | 0.389 | 0.422 | |||||||||
Well | 1 | (2%) | 8 | (5%) | 1 | (3%) | 2 | (5%) | |||
Moderate | 16 | (30%) | 52 | (35%) | 9 | (23%) | 14 | (36%) | |||
Poor | 30 | (56%) | 65 | (43%) | 22 | (56%) | 15 | (38%) | |||
Unknown | 7 | (13%) | 25 | (17%) | 7 | (18%) | 8 | (21%) | |||
Chemotherapy | 0.228 | 1.000 | |||||||||
Yes | 30 | (56%) | 69 | (46%) | 22 | (56%) | 22 | (56%) | |||
No | 24 | (44%) | 81 | (54%) | 17 | (44%) | 17 | (44%) | |||
Gastrectomy type | 0.011* | 0.065 | |||||||||
Total | 10 | (19%) | 56 | (37%) | 6 | (15%) | 13 | (33%) | |||
Partial | 44 | (81%) | 94 | (63%) | 33 | (85%) | 26 | (67%) | |||
Lymph node yielde | Mean (sd) | c15.7 | c(10.1) | 21.7 | c(12.0) | 0.001* | 15.0 | c(10.4) | 20.3 | c(11.5) | 0.050* |
Splenectomy +/− pancreatectomy | 0.581 | 1.000 | |||||||||
No | 53 | (98%) | 145 | (97%) | 38 | (97%) | 38 | (97%) | |||
Yes | 1 | (2%) | 5 | (3%) | 1 | (3%) | 1 | (3%) |
Survival
Univariate analysis of complications and 30-day mortality
Variable | Before PSM (n = 204) | aAfter PSM (n = 78) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
D1/D1+ (n = 54) | D2 (n = 150) | D1/D1+ (n = 39) | D2 (n = 39) | ||||||||
n
| % |
n
| % |
p
b
|
n
| % |
n
| % |
p
b
| ||
Clavien-Dindo classification | 0.454 | 0.227 | |||||||||
I | 7 | (13%) | 31 | (21%) | 3 | (7%) | 10 | (24%) | |||
II | 15 | (28%) | 50 | (33%) | 9 | (21%) | 11 | (26%) | |||
III | 3 | (6%) | 7 | (5%) | 3 | (7%) | 1 | (2%) | |||
IV | 2 | (4%) | 4 | (3%) | 1 | (2%) | 1 | (2%) | |||
V | 3 | (6%) | 2 | (1%) | 1 | (2%) | 0 | (0%) | |||
30-day mortality | Yes | 3 | (6%) | 2 | (1%) | 0.085 | 1 | (2%) | 0 | (0%) | 0.314 |
No | 51 | (94%) | 148 | (99%) | 41 | (98%) | 42 | (100%) |
Variables | Before PSM (n = 204) | After PSM (n = 78) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of patients | aComplications | 30-day mortality | No. of patients | aComplications | 30-day mortality | |||||||||
n
| % |
p
|
n
| % |
p
|
n
| % |
p
|
n
| % |
p
| |||
Age | 0.008* | 0.557 | 0.006* | 0.265 | ||||||||||
< 70 | 108 | 57 | (53%) | 2 | (2%) | 43 | 16 | (37%) | 0 | (0%) | ||||
≥ 70 | 96 | 68 | (71%) | 3 | (3%) | 35 | 24 | (69%) | 1 | (3%) | ||||
Gender | 0.892 | 0.117 | 0.624 | 0.502 | ||||||||||
Male | 138 | 85 | (62%) | 5 | (4%) | 54 | 28 | (52%) | 1 | (2%) | ||||
Female | 66 | 40 | (61%) | 0 | (0%) | 24 | 11 | (46%) | 0 | (0%) | ||||
BMI | 0.502 | 0.228 | 0.784 | 0.595 | ||||||||||
≥ 30 | 29 | 15 | (52%) | 1 | (3%) | 17 | 8 | (47%) | 0 | (0%) | ||||
< 30 | 135 | 79 | (59%) | 1 | (1%) | 61 | 31 | (51%) | 1 | (2%) | ||||
Hemoglobin level | 0.830 | 0.075 | 0.530 | 0.688 | ||||||||||
≤ 100 | 25 | 17 | (68%) | 2 | (8%) | 12 | 7 | (58%) | 0 | (0%) | ||||
> 100 | 173 | 107 | (62%) | 3 | (2%) | 66 | 31 | (47%) | 1 | (2%) | ||||
Tumor location | 0.009* | 0.406 | 0.070 | 0.302 | ||||||||||
Proximal, middle | 81 | 57 | (70%) | 2 | (2%) | 38 | 23 | (61%) | 1 | (3%) | ||||
Distal | 107 | 55 | (51%) | 1 | (1%) | 40 | 16 | (40%) | 0 | (0%) | ||||
Tumor stage (TNM) | 0.145 | 0.768 | 0.425 | 0.087 | ||||||||||
III, IV | 67 | 46 | (69%) | 2 | (3%) | 19 | 11 | (58%) | 1 | (5%) | ||||
I, II | 131 | 76 | (58%) | 3 | (2%) | 55 | 26 | (47%) | 0 | (0%) | ||||
Chemotherapy | 0.849 | 0.699 | 1.000 | 0.252 | ||||||||||
Yes | 99 | 60 | (61%) | 2 | (2%) | 34 | 17 | (50%) | 0 | (0%) | ||||
No | 105 | 65 | (62%) | 3 | (3%) | 44 | 22 | (50%) | 1 | (2%) | ||||
Gastrectomy type | 0.020* | 0.021* | 0.018* | 0.076 | ||||||||||
Total | 66 | 48 | (73%) | 4 | (6%) | 19 | 14 | (74%) | 1 | (5%) | ||||
Partial | 138 | 77 | (56%) | 1 | (1%) | 59 | 25 | (42%) | 0 | (0%) | ||||
Lymphadenectomy type | 0.314 | 0.085 | 0.113 | 0.314 | ||||||||||
D1/D1+ | 54 | 30 | (56%) | 3 | (6%) | 39 | 16 | (41%) | 1 | (3%) | ||||
D2 | 150 | 95 | (63%) | 2 | (1%) | 39 | 23 | (59%) | 0 | (0%) | ||||
Splenectomy +/− pancreatectomy | 0.783 | 0.694 | 1.000 | 0.870 | ||||||||||
Yes | 6 | 4 | (67%) | 0 | (0%) | 2 | 1 | (50%) | 0 | (0%) | ||||
No | 198 | 121 | (61%) | 5 | (3%) | 76 | 38 | (50%) | 1 | (1%) |
Cox proportional hazards regression analysis
Univariable Cox regression analysis | Multivariable Cox regression analysis | ||||||
---|---|---|---|---|---|---|---|
Parameters | HR | 95%CI |
p
| HR | 95%CI |
p
| |
Before PSM | |||||||
Age | ≥ 70/< 70 | 1.172 | 0.721–1.907 | 0.521 | |||
Gender | F/M | 1.045 | 0.622–1.756 | 0.867 | |||
BMI | < 30/≥30 | 1.138 | 0.673–1.924 | 0.629 | |||
Hemoglobin level | ≤ 100/> 100 | 1.682 | 0.854–3.314 | 0.133 | |||
Tumor location | Proximal, middle/Distal | 1.608 | 0.948–2.728 | 0.078 | |||
TNM stage (AJCC classification) | III, IV/ I, II | 3.925 | 2.402–6.414 | 0.000* | 3.519 | 2.067–5.993 | 0.000* |
Chemotherapy | Yes/No | 1.205 | 0.740–1.963 | 0.453 | |||
Lymphadenectomy type | D1/D1+/D2 | 1.338 | 0.787–2.272 | 0.282 | |||
Gastrectomy type | Total/Partial | 1.803 | 1.102–2.949 | 0.019* | |||
aOverall complication | Yes/No | 3.169 | 1.895–5.298 | 0.000* | 2.971 | 1.714–5.149 | 0.000* |
After PSM | |||||||
Age | ≥ 70/< 70 | 1.666 | 0.714–3.881 | 0.237 | |||
Gender | M/F | 1.069 | 0.416–2.744 | 0.890 | |||
BMI | < 30/≥ 30 | 3.463 | 0.808–14.840 | 0.094 | |||
Hemoglobin level | ≤ 100/> 100 | 1.596 | 0.542–4.701 | 0.396 | |||
Tumor location | Proximal, middle/Distal | 1.305 | 0.572–2.981 | 0.527 | |||
TNM stage (AJCC classification) | III, IV/ I, II | 6.627 | 2.640–16.638 | 0.000* | 4.218 | 1.560–11.407 | 0.005* |
Chemotherapy | Yes/No | 1.318 | 0.573–3.034 | 0.516 | |||
Lymphadenectomy type | D1/D1+/D2 | 3.490 | 1.308–9.311 | 0.013* | 4.353 | 1.511–12.541 | 0.006* |
Gastrectomy type | Total/Partial | 2.577 | 1.074–6.184 | 0.034* | 2.883 | 0.846–9.829 | 0.091 |
aOverall complication | Yes/No | 4.480 | 1.901–10.560 | 0.001* | 3.849 | 1.342–11.040 | 0.012* |